Verospiron (spironolactone)

Instructions for Verospiron (spironolactone)

Active substances
Spironolactone

Release Form
Capsules

Composition
The active ingredient is Spironolactone (Spironolactone). Active ingredient concentration (mg): 50

"Pharmacological properties Verospiron

Official instructions for Verospiron indicate that it is a potassium-sparing diuretic. The main active ingredient interacts with the hormone aldosterone of the adrenal cortex and inhibits its effect. Sodium, chloride, and water are not reabsorbed by the renal tubules, whereas potassium and urea are absorbed through the endothelium of the glomerulus into the blood. Increasing urination lowers blood pressure and eliminates edema. Urinary-excretion effect appears only after 3-5 days of administration. Verospiron has little to no effect on renal tubule function and does not upset the acid-base balance in the body.

Pharmacokinetics Verospiron

When taken by mouth, Verospiron is quickly and completely absorbed from the gastrointestinal tract. Its bioavailability is about 100%; eating increases this percentage to 100%. The drug binds almost completely to plasma proteins, about 98%. With a maximum daily dose of 100 mg, a peak blood concentration of 80 ng/mL is reached within 15 days, and the time to reach the maximum concentration after the morning dose is 2 to 6 hours. In the liver, the drug biotransforms to form active sulfur-containing metabolites 7-alpha-thiomethylspironolactone and cannenon. Carenone reaches its peak concentration in 2 to 4 hours and has a 90% plasma protein binding. Spironolactone does not penetrate well into organs and tissues, although it and its metabolites can cross the placental barrier and canrenone can penetrate into breast milk. The volume of distribution is about 0.05 L/kg. The half-life is 13 to 24 hours. The drug is excreted by the kidneys, with 50% excreted as metabolites, 10% unchanged, and partly via the intestines. Cannenone elimination (mainly by the kidneys) occurs in two phases, with a half-life of 2 to 3 hours in the first phase and 12 to 96 hours in the second. In cirrhosis and heart failure, the half-life increases, but cumulation, which may occur with chronic kidney failure and hyperkalemia, is absent.

Indications for use Verospiron

Verospiron is used for combination therapy of essential hypertension. It can also be used to treat edema in chronic heart failure, either alone or in combination with standard therapies. It can be used in conditions that cause secondary hyperaldosteronism, including cirrhosis with ascites or edema, nephrotic syndrome, and other conditions accompanied by edema. Additionally, verospiron can be used as an adjunct to prevent hypokalemia and hypomagnesemia in the treatment of diuretics and in the absence of other potassium correction methods. A short course of treatment may be prescribed to establish the diagnosis of primary hyperaldosteronism (Conn syndrome)."